Switch theme
Sign up to access all valuation multiples
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
2010
11K+
LTM Revenue $4.4B
LTM EBITDA -$80.6M
$26.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BeOne Medicines has a last 12-month revenue (LTM) of $4.4B and a last 12-month EBITDA of -$80.6M.
In the most recent fiscal year, BeOne Medicines achieved revenue of $485M and an EBITDA of -$50.5M.
BeOne Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BeOne Medicines valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | XXX | $485M | XXX | XXX | XXX |
| Gross Profit | $3.8B | XXX | $410M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | -$80.6M | XXX | -$50.5M | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -10% | XXX | XXX | XXX |
| EBIT | -$217M | XXX | -$72.4M | XXX | XXX | XXX |
| EBIT Margin | -5% | XXX | -15% | XXX | XXX | XXX |
| Net Profit | -$264M | XXX | -$82.1M | XXX | XXX | XXX |
| Net Margin | -6% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, BeOne Medicines's stock price is HKD 157 (or $20).
BeOne Medicines has current market cap of HKD 220B (or $28.1B), and EV of HKD 208B (or $26.5B).
See BeOne Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.5B | $28.1B | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, BeOne Medicines has market cap of $28.1B and EV of $26.5B.
BeOne Medicines's trades at 54.7x EV/Revenue multiple, and -525.7x EV/EBITDA.
Equity research analysts estimate BeOne Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BeOne Medicines has a P/E ratio of -106.2x.
See valuation multiples for BeOne Medicines and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.1B | XXX | $28.1B | XXX | XXX | XXX |
| EV (current) | $26.5B | XXX | $26.5B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 54.7x | XXX | XXX | XXX |
| EV/EBITDA | -329.6x | XXX | -525.7x | XXX | XXX | XXX |
| EV/EBIT | -122.1x | XXX | -366.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -106.2x | XXX | -341.7x | XXX | XXX | XXX |
| EV/FCF | -141.0x | XXX | -311.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeOne Medicines's last 12 month revenue growth is 27%
BeOne Medicines's revenue per employee in the last FY averaged $44K, while opex per employee averaged $44K for the same period.
BeOne Medicines's rule of 40 is -19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BeOne Medicines's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BeOne Medicines and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 256% | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | -755% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -19% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeOne Medicines acquired XXX companies to date.
Last acquisition by BeOne Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . BeOne Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BeOne Medicines founded? | BeOne Medicines was founded in 2010. |
| Where is BeOne Medicines headquartered? | BeOne Medicines is headquartered in Hong Kong. |
| How many employees does BeOne Medicines have? | As of today, BeOne Medicines has 11K+ employees. |
| Who is the CEO of BeOne Medicines? | BeOne Medicines's CEO is Mr. John V. Oyler. |
| Is BeOne Medicines publicy listed? | Yes, BeOne Medicines is a public company listed on HKG. |
| What is the stock symbol of BeOne Medicines? | BeOne Medicines trades under 06160 ticker. |
| When did BeOne Medicines go public? | BeOne Medicines went public in 2018. |
| Who are competitors of BeOne Medicines? | Similar companies to BeOne Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BeOne Medicines? | BeOne Medicines's current market cap is $28.1B |
| What is the current revenue of BeOne Medicines? | BeOne Medicines's last 12 months revenue is $4.4B. |
| What is the current revenue growth of BeOne Medicines? | BeOne Medicines revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of BeOne Medicines? | Current revenue multiple of BeOne Medicines is 6.0x. |
| Is BeOne Medicines profitable? | Yes, BeOne Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BeOne Medicines? | BeOne Medicines's last 12 months EBITDA is -$80.6M. |
| What is BeOne Medicines's EBITDA margin? | BeOne Medicines's last 12 months EBITDA margin is -2%. |
| What is the current EV/EBITDA multiple of BeOne Medicines? | Current EBITDA multiple of BeOne Medicines is -329.6x. |
| What is the current FCF of BeOne Medicines? | BeOne Medicines's last 12 months FCF is -$188M. |
| What is BeOne Medicines's FCF margin? | BeOne Medicines's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of BeOne Medicines? | Current FCF multiple of BeOne Medicines is -141.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
